ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

910
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Regulatory

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Novartis has received full approval from the U.S. Food and Drug Administration (FDA ) for Fabhalta to treat adults...
Clinical

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Analysis of the phase 3 results on camlipixant, which was a major potential blockbuster expected to be the standout...
Commercial

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Dimerix has acquired DMX-652, a phase 2-ready drug candidate for acute kidney injury (AKI), from Mission Therapeutics in a...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you